CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.
Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang MS, Gauthier S, Rouleau GA, Poirier J, Bennett DA, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.
Neurol Genet. 2018 Jan 30;4(1):e216. doi: 10.1212/NXG.0000000000000216. eCollection 2018 Feb.
Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.
Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.
J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924.
Identifying incipient dementia individuals using machine learning and amyloid imaging.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MS, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.
Neurobiol Aging. 2017 Nov;59:80-90. doi: 10.1016/j.neurobiolaging.2017.06.027. Epub 2017 Jul 11.
Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
Gauthier S, Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedetti AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P.
Neurology. 2017 Oct 31;89(18):1931. doi: 10.1212/WNL.0000000000004593.
Characterizing biomarker features of cognitively normal individuals with ventriculomegaly.
Li X, Ba M, Ng KP, Mathotaarachchi S, Pascoal TA, Rosa-Neto P, Gauthier S.
Alzheimers Dement (Amst). 2017 Sep 5;10:12-21. doi: 10.1016/j.dadm.2017.08.001. eCollection 2018.
Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer’s Disease.
Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL.
IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768. doi: 10.1109/TMI.2017.2693978. Epub 2017 Apr 12.
Synergistic interaction between amyloid and tau predicts the progression to dementia.
Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.
Alzheimers Dement. 2017 Jun;13(6):644-653. doi: 10.1016/j.jalz.2016.11.005. Epub 2016 Dec 23.
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.
Neurology. 2017 May 9;88(19):1814-1821. doi: 10.1212/WNL.0000000000003916. Epub 2017 Apr 12.
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.
Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.